Chancellor of Health Affairs, President and CEO of Duke Medicine
2004 - 2015
DegreesMcGill University BS and MD (cardiology)
Chairman of Medicine at Harvard and Stanford before joining Duke, Dzau is a cardiologist who's work on angiotensin-converting-enzyme led to the development of ACE inhibitor therapy for hypertension. He guided the formation of the Duke-NUS Medical School in Singapore, and helped open the North Carolina Research Campus in Kannapolis and the Duke-led longitudinal MURDOCK study there. Left Duke in 2015 to become president of the National Academy of Medicine.